Laurus Labs Moat Analysis: Score & Risks
Laurus Labs Ltd.
A first-pass moat teardown of Laurus Labs Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow → wide read — primary edge in Intangible Assets. Provisional, single-pass evidence.
Laurus Labs Ltd. scores 5.58 on MoatSCORE 6.0 — a narrow → wide moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“we made significant investments in CAPEX so far in peptide development and manufacturing infrastructure to meet our current and future capacity requirements”
“This principle ensures that the same discipline is applied whether we are serving regulated markets, emerging markets, global health programmes or strategic CDMO customers.”
“With backward integration, stringent regulatory compliance, and operational excellence, we deliver reliable and cost-effective solutions to global pharmaceutical markets.”
“We have allocated $25 million to the GMP facility which is under construction right now”
“The pharmaceutical industry is highly competitive, with companies vying for market share in generic and specialty medicine sectors. For us, the focus on complex generics and niche therapeutic areas”
“we are very comfortable to say we'll maintain gross margin for sure despite our challenges on the solvent price and all. We are confident.”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 6.0 — clears the gate. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 113 Indian companies we have scored for moat durability — 88 narrow, 25 narrow-trending-wide, none wide. The full ranked read: Wide-Moat Stocks in India: We Scored 113 Companies and Found None. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion